CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
HYVE.Promo Launches as APAC’s Newest Print-on-Demand Platform for Corporate Gifting — Powered by AI and Built for Scale
AI Labs Introduces AI-Assisted Crypto Trading Platform Focused on Data Analysis and Automated Execution
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Core Concepts Physiotherapy Partners with Podiatry Quest to Deliver Enhanced Assessments for Patients with Plantar Fasciitis
AI Safety Asia Advances Crisis Diplomacy and Evidence-Based AI Governance at India AI Impact Summit 2026
Domoa Private Limited Launches Initiative to Mainstream 3D-Printed Real Estate in Singapore and Southeast Asia
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Malaysian Content Creators Immerse Themselves in Jiaxing’s Spring Festival Festivities, Discovering the Depth and Warmth of a Jiangnan Chinese New Year
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
